Skip to main content
. Author manuscript; available in PMC: 2021 Jul 7.
Published in final edited form as: Ann Surg Oncol. 2019 Sep 12;26(13):4782–4790. doi: 10.1245/s10434-019-07800-2

Figure 4: Humanized SFRP2 mAb inhibits tumor growth in angiosarcoma and breast cancer.

Figure 4:

(a) Pharmacokinetic plot showing the decrease in concentration of hSFRP2 mAb in the serum of mice over time after a single i.v. injection of 4 mg/kg. AUC: Area Under Curve; T 1/2: Half-life; CL: clearance; Vd: volume of distribution; Cmax: maximum serum concentration. Each data point represents the mean ± SEM of the measurements of at least 3 independent samples (n=3 per time point). (b) Nude mice with SVR angiosarcoma allografts were treated with hSFRP2 mAb or IgG1 control. There was a 43% reduction in tumor growth in the hSFRP2 mAb-treated mice (n=10, *p<0.05). (c) Effects of IgG1 treatment vs hSFRP2 mAb on Hs578T tumor volume in vivo over time. Nude mice with Hs578T xenografts were treated with hSFRP2 mAb or IgG1 control for a total of 52 days. Day is counted from day of first treatment, which was 30 days from tumor inoculation. There was a 61% reduction in tumor volume in the hSFRP2 mAb treated mice, n=11, *p<0.05).